StockWatch
·

Dishman Carbogen Amcis Ltd Q2 FY27 Results

DCALQ2 FY27 Results
Filing
Result:Poor· Market: Crashed#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue507.3725.1%22.3%
Total Income510.9326.6%22.7%
Expenditure591.9320.6%6.1%
PBT-81.0058.1%365.2%
Net Profit-66.7315.3%202.2%
OPM9.06%0.44pp13.75pp
NPM-13.06%4.74pp22.94pp
EPS-4.26215.4%202.4%
View full financials

CDMO/pharma core revenue fell 22% YoY with OPM collapsing from 22.8% to 9.1%, driving a second straight net loss (₹-66.7 Cr) versus a year-ago profit — a clear deterioration, not a turnaround.

Q2 FY-2027 RESULTS · DCAL

Dishman Carbogen Amcis swings to ₹66.7 Cr consolidated loss, revenue down 22% YoY

PAT -202.24% YoY · revenue -22.26% · margins compressing · miss vs street

14 Nov 2026 · 3 min read
Revenue

₹507.37 Cr

-22.26% YoY

PAT (consolidated)

₹-66.73 Cr

-202.24% YoY

Net margin

-13.06%

-22.9pp YoY

EPS

₹-4.26

Dishman Carbogen Amcis reported a consolidated net loss of ₹66.7 Cr for Q2 FY27, against a ₹65.3 Cr profit in Q2 FY26 and widening from a ₹57.9 Cr loss in Q1 FY27 — a second straight loss-making quarter that deepened 15% sequentially. Consolidated revenue fell 22.3% YoY and 25.1% QoQ to ₹507.4 Cr. The print missed our pre-result on-plan range of ₹680-720 Cr revenue and ₹45-55 Cr net profit by a wide margin — the business was expected to recover from Q1's deferral-driven loss and instead the shortfall widened, which is also a clear miss against Street consensus (Sell-rated, ₹165 target, ~5% downside from ₹173.7 pre-result) that had been pricing in execution risk on deferred CDMO work.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹507.37 Cr-25.1%-22.3%
Expenses₹591.93 Cr-20.6%-6.1%
PAT₹-66.73 Cr-15.29%-202.24%
Net margin-13.06%-4.7pp-22.9pp
EPS₹-4.26-215.4%-202.4%

The margin bridge explains most of the damage: operating margin collapsed to 9.06% from 22.81% a year ago (roughly flat versus 8.87% in Q1 FY27), and net margin swung to -13.15% from +9.88%. Employee benefit expense (₹321.6 Cr) fell only 3.4% YoY even as revenue fell 22.3%, so the topline decline flowed almost straight through to the operating line. Measured against management's standing FY26 EBITDA margin guidance of 19.5-20% (reiterated on the February 2026 call), this quarter's 9.06% is a clear miss, and the longer-term target of restoring consolidated EBITDA margins to 25-26% within two years looks materially further away. No management press release accompanies this filing to explain the shortfall or reaffirm guidance.

₹
128.81148.1167.39186.68205.97172.9208-1109-0209-2510-2111-1211-13
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹172.92, up 13% over the past month of trading.

₹ Cr
-82.57-28.0126.5581.1143.09Q4 FY25rev ₹716 Cr23.41Q1 FY26rev ₹708 Cr65.27Q2 FY26rev ₹653 Cr-12.97Q3 FY26rev ₹720 Cr-57.88Q1 FY27rev ₹678 Cr-66.73Q2 FY27rev ₹507 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (3 FY-2026 call)
Management reiterates its full-year FY26 EBITDA margin guidance of 19.5-20%, anticipating a stronger Q4 to offset a weaker Q3 product mix. The company projects a significant long-term ramp-up, targeting INR 500 crores in revenue from its India operations within 12-18 months, driven by a substantial INR 1,200 crore RFP

— This quarter: missed

Standalone (the India parent) posted a narrower ₹25.3 Cr loss on ₹83.6 Cr revenue — worse in percentage terms (NPM -30.2%) but small in absolute rupees, confirming that both the bulk of revenue and the bulk of the consolidated loss sit in the European/Swiss CDMO subsidiaries; readers comparing the two numbers should not read the smaller standalone loss as the fuller picture. The quarter also saw the company raise ₹53 Cr of fresh NCDs (₹38 Cr and ₹15 Cr tranches, on top of earlier ₹75 Cr and ₹15 Cr issuances) with consolidated debt-equity rising to 0.47x from 0.35x YoY, alongside late-October/early-November promoter family settlement and share-transfer disclosures.

  • W1

    H2 EBITDA margin recovery toward management's FY26 guidance of 19.5-20% — Q2 printed just 9.06%, a wide gap to close.

  • W2

    Debt trajectory: consolidated borrowings at ₹3,163.7 Cr (debt-equity 0.47x) after ₹53 Cr of fresh NCDs this quarter — watch for further issuance or stabilization.

  • W3

    French facility breakeven guided for FY27 — a ₹66.7 Cr consolidated loss this quarter suggests that remains unmet so far.

Both statements clean/legible; no exceptional items in current quarter or year-ago quarter (the ₹1.69 Cr QIP write-off sits only in Q1 FY27), so raw YoY = adjusted YoY; no minority interest (wholly-owned group); standalone is India-parent-only and far smaller in scale than consolidated.

Informational and educational content only. Not investment advice.